Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Dr Kenneth J Widder \"Ken\"
AddedMar 31, 2024
UpdatedMay 1, 2026
Dr Kenneth J Widder \"Ken\"

Dr Kenneth J Widder \"Ken\"

Board Member, QuidelOrtho

Dr Kenneth J Widder \"Ken\"'s Career

QuidelOrtho
QuidelOrtho

San Diego, CA, US

Board Member· Board
Luminous Medical
Luminous Medical

Carlsbad, CA, US

Board Member· Board
Femta Pharmaceuticals
Femta Pharmaceuticals

San Diego, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Dr Kenneth J Widder \"Ken\"'s Career

QuidelOrtho
QuidelOrtho
Public7k2021San Diego, CA, US
Board Member· Board

Leadership at QuidelOrtho

Douglas C. BryantDouglas C. BryantCEO
Kenneth BuechlerKenneth BuechlerBoard Member
Mary PolanMary PolanBoard Member
Doug BryantDoug BryantBoard Member
Luminous Medical
Luminous Medical
Series A$4.4M302005Carlsbad, CA, US
Board Member· Board

Leadership at Luminous Medical

Richard ThompsonRichard ThompsonFounder
Joe MandatoJoe MandatoBoard Member
M RobinsonM RobinsonBoard Member
F T Watkins \"Jay\"F T Watkins \"Jay\"Board Member
Dr Michael Lynn \"Mike\"Dr Michael Lynn \"Mike\"Board Member
Femta Pharmaceuticals
Femta Pharmaceuticals
Acquired$23.5M02008San Diego, CA, US
Board Member· Board

Leadership at Femta Pharmaceuticals

Jay M. ShortJay M. ShortBoard Member
Dr Per A PetersonDr Per A PetersonBoard Member

Similar to Femta Pharmaceuticals

FabrusFabrusSan Diego, CA, USMonoclonal Antibodiesest. 2007FabrusSan Diego, CA, US · est. 2007

Fabrus, Inc: A US-based biotech company specializing in the development of therapeutic monoclonal antibodies.

Seed · $2M6
Fortis TherapeuticsFortis TherapeuticsSan Diego, CA, USAntibody Drug Therapiesest. 2016Fortis TherapeuticsSan Diego, CA, US · est. 2016

Fortis Therapeutics, a biotech firm, develops innovative antibody drug therapies for advanced cancers.

Series A · $58M75
IgenicaIgenicaBurlingame, CA, USBiopharmaceuticalsest. 2008IgenicaBurlingame, CA, US · est. 2008

Igenica, Inc.: A biotherapeutics firm creating monoclonal antibodies for cancer treatment in the US.

Pre-Seed · $80.6M11
NanoPharmaceuticalsNanoPharmaceuticalsRensselaer, NY, USTherapeuticsest. 2013NanoPharmaceuticalsRensselaer, NY, US · est. 2013

Clinical-stage company innovating targeted therapeutics for cancer and inflammatory diseases.

Pre-Seed · $6M7

Dr Kenneth J Widder \"Ken\"'s Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Dr Kenneth J Widder \"Ken\"

Kenneth WuKenneth WuBoard Member · Presidio MedicalJames W KenneyJames W KenneyBoard Member · PhazarKenneth H Traub \"Ken\"Kenneth H Traub \"Ken\"Board Member · AthersysKen MaleKen MaleBoard Member · TheInfoProKenneth M KirkpatrickKenneth M KirkpatrickBoard Member · ZonesKenneth J Melkus \"Ken\"Kenneth J Melkus \"Ken\"Board Member · Ardent Health